Rossana Intini

Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes

Fotios Loupakis, Ilaria Depetris, Paola Biason et al. · The Oncologist · 2020 · 107 citations · Full text

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

Élena Elez, Javier Ros, J. Fernández et al. · Nature Medicine · 2022 · 103 citations · Full text

The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors

Francesca Corti, Sara Lonardi, Rossana Intini et al. · European Journal of Cancer · 2021 · 102 citations

Pan-immune-inflammation Value, Cancer Immunosurveillance, Medicine +12

A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study

Fotios Loupakis, Rossana Intini, Chiara Cremolini et al. · European Journal of Cancer · 2019 · 69 citations · Full text

Prognostic Biomarkers, Gastrointestinal Oncology, Medicine +7

Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors

Paolo Manca, Francesca Corti, Rossana Intini et al. · European Journal of Cancer · 2023 · 50 citations · Full text

Medicine, Immune Checkpoint Inhibitors, Immunology +8